Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis

Chen L, Li Chen, Tang L, Lan Tang, Weiwei Dong, Dong W, Zeng S, Shuhua Zeng, Sisi Wu, Wu S, Ye H, Hong Ye
Pakistan journal of pharmaceutical sciences · 2026 · vol. 39(4) , pp. 1121–1133 · doi:10.36721/PJPS.2026.39.4.REG.14460.1 · PMID:41761808
meta-analysis OA: gold public-domain-us
🔓 Open OA copy Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

This meta-analysis of 12 trials found that goserelin acetate implants significantly improved hormone levels and treatment outcomes for endometriosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-22 · read from full text ⓘ

This meta-analysis evaluated the impact of goserelin acetate implants on hormone levels and clinical outcomes in patients with endometriosis. The researchers analyzed data from twelve controlled trials involving 1,299 participants to assess changes in luteinizing hormone, follicle-stimulating hormone, and estradiol levels following treatment. Results indicated that the implant significantly improved overall treatment efficacy while reducing pain scores, recurrence rates, and adverse reactions compared to controls. This paper is centrally about endometriosis — specifically evaluating the hormonal and clinical effects of goserelin acetate implant therapy for the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity. OBJECTIVE: This study aimed to investigate the impact of goserelin acetate implants on hormone levels in patients with endometriosis using a systematic review methodology. METHODS: A comprehensive search of databases including PubMed, VIP, CNKI and Wanfang was conducted for controlled trials from 2000 to 2025. RESULTS: 12 included trials (1,299 participants) showed that goserelin acetate implant treatment significantly improved endometriosis [OR: 5.82, 95% CI (3.20, 10.59), P<0.000001], increased luteinizing hormone [MD: -2.04, 95% CI (-2.26, -1.83), P<0.00001], follicle-stimulating hormone [MD: -2.34, 95% CI (-2.58, -2.10), P<0.00001] and estradiol levels [MD: -1.89, 95% CI (-2.11, -1.66), P<0.00001], while reducing Visual Analog Scale scores [MD: -0.41, 95% CI (-0.48, -0.34), P<0.000001], recurrence rates [OR: 0.15, 95% CI (0.09, 0.24), P<0.00001] and adverse reactions [OR: 0.19, 95% CI (0.06, 0.55), P<0.00001]. The funnel plot exhibited an inverted funnel shape with relative symmetry, indicating no significant publication bias. CONCLUSION: The study demonstrates that goserelin acetate implants can effectively enhance overall treatment outcomes and regulate hormone levels in endometriosis patients.
Full text 1,520 characters · extracted from oa-html · click to expand
original articles Li Chen, Lan Tang, Weiwei Dong, Shuhua Zeng, Sisi Wu, Hong Ye Background: Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity. Objective: This study aimed to investigate the impact of goserelin acetate implants on hormone levels in patients with endometriosis using a systematic review methodology. Methods: A comprehensive search of databases including PubMed, VIP, CNKI and Wanfang was conducted for controlled trials from 2000 to 2025. Results: 12 included trials (1,299 participants) showed that goserelin acetate implant treatment significantly improved endometriosis [OR: 5.82, 95% CI (3.20, 10.59), P<0.000001], increased luteinizing hormone [MD: -2.04, 95% CI (-2.26, -1.83), P<0.00001], follicle-stimulating hormone [MD: -2.34, 95% CI (-2.58, -2.10), P<0.00001] and estradiol levels [MD: -1.89, 95% CI (-2.11, -1.66), P<0.00001], while reducing Visual Analog Scale scores [MD: -0.41, 95% CI (-0.48, -0.34), P<0.000001], recurrence rates [OR: 0.15, 95% CI (0.09, 0.24), P<0.00001] and adverse reactions [OR: 0.19, 95% CI (0.06, 0.55), P<0.00001]. The funnel plot exhibited an inverted funnel shape with relative symmetry, indicating no significant publication bias. Conclusion: The study demonstrates that goserelin acetate implants can effectively enhance overall treatment outcomes and regulate hormone levels in endometriosis patients. Endometriosis Goserelin acetate implant Hormone levels Meta-analysis

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-28T06:13:43.407401+00:00
pubmed
last seen: 2026-09-29T06:11:59.123951+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine